

Special Issue

Current Status and Future Prospects of Histopathology in Cancer Diagnosis

Message from the Guest Editors

In recent years, the field of histopathology has undergone several innovations, and tissue analysis has substantially contributed to improving the current knowledge on cancer pathophysiology. Indeed, advancements in the fields of cancer genomics and epigenomics have allowed for the identification of new tumor entities and the refinement of histological classifications. This Special Issue aims to highlight the most recent advances in the field of oncological histopathology and welcome original research articles and systematic reviews focused on cutting-edge discoveries in cancer diagnostics, with particular interest in studies that aim to identify correlations between tumor morphology and immunophenotypical and/or molecular features in human cancers. We also encourage fellow researchers to submit articles on new tissue biomarkers that may provide prognostic information and aid in selecting the most appropriate therapeutic strategies for patients with cancer.

Guest Editors

Dr. Serena Ammendola

Division of Pathology, Department of Diagnostics and Public Health, Azienda Ospedaliera Universitaria Integrata of Verona, 37134 Verona, Italy

Dr. Valeria Barresi

Department of Diagnostics and Public Health, P.le L.A. Scuro, University of Verona, 37129 Verona, Italy

Deadline for manuscript submissions

31 October 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/206157

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).